These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22907123)

  • 21. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
    Biermasz NR; Roelfsema F; Pereira AM; Romijn JA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):223-34. PubMed ID: 19527094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
    Cendros JM; Peraire C; Trocóniz IF; Obach R
    Metabolism; 2005 Oct; 54(10):1276-81. PubMed ID: 16154424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
    Bevan JS; Newell-Price J; Wass JA; Atkin SL; Bouloux PM; Chapman J; Davis JR; Howlett TA; Randeva HS; Stewart PM; Viswanath A
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):343-9. PubMed ID: 17892497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.
    Steffin B; Gutt B; Bidlingmaier M; Dieterle C; Oltmann F; Schopohl J
    Eur J Endocrinol; 2006 Jul; 155(1):73-8. PubMed ID: 16793952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
    Mariani P; Blumberg J; Landau A; Lebrun-Jezekova D; Botton E; Beatrix O; Mayeur D; Herve R; Maisonobe P; Chauvenet L
    J Clin Oncol; 2012 Dec; 30(35):4337-43. PubMed ID: 23109694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
    Bisschops R; De Ruyter V; Demolin G; Baert D; Moreels T; Pattyn P; Verhelst H; Lepoutre L; Arts J; Caenepeel P; Ooghe P; Codden T; Maisonobe P; Petrens E; Tack J
    Clin Ther; 2016 Aug; 38(8):1902-1911.e2. PubMed ID: 27423779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly.
    Colao A; Auriemma RS; Rebora A; Galdiero M; Resmini E; Minuto F; Lombardi G; Pivonello R; Ferone D
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):237-45. PubMed ID: 19094074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].
    Robin E; Lebrec D; Hammel P; Bernades P; Ruszniewski P
    Gastroenterol Clin Biol; 1996; 20(11):1014-6. PubMed ID: 9119171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E; Procopio G; Catena L; Martinetti A; De Dosso S; Ricci S; Lecchi AS; Boscani PF; Iacobelli S; Carteni G; De Braud F; Loli P; Tartaglia A; Bajetta R; Ferrari L
    Cancer; 2006 Nov; 107(10):2474-81. PubMed ID: 17054107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly.
    Chang TC; Chang TJ; Chen MH; Hsiao YL; Tsai KS
    J Formos Med Assoc; 1998 Oct; 97(10):684-9. PubMed ID: 9830278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
    Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
    Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
    Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
    Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.
    Scherübl H; Wiedenmann B; Riecken EO; Thomas F; Böhme E; Räth U
    Eur J Cancer; 1994; 30A(10):1590-1. PubMed ID: 7833124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.